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FLIP (FLICE Inhibitory Protein) is a recently identi-
®ed intracellular inhibitor of caspase-8 activation that
potently inhibits cell death mediated by all death
receptors including Fas and TRAIL. FLIP has
recently been shown to favor tumor growth and
immune escape in mouse tumor models. We ana-
lyzed FLIP expression by immunohistochemistry in
a panel of 61 benign and malignant human melano-
cytic skin lesions. FLIP expression was undetectable
in all but one benign melanocytic lesion (31/32,
97%). In contrast, FLIP was strongly expressed in
most melanomas (24/29 = 83%). Overexpression of
FLIP by transfection in a Fas- and TRAIL-sensitive
human melanoma cell line rendered this cell line
more resistant to death mediated by both TRAIL
and FasL. Selective expression of FLIP by human
melanomas may confer in vivo resistance to FasL and
TRAIL, thus representing an additional mechanism
by which melanoma cells escape immune destruc-
tion. Key words: apoptosis/death receptors/melanoma. J
Invest Dermatol 117:360±364, 2001
A
poptosis is a tightly regulated form of cell death that is
implicated in the defence against pathogens and
cancer. Apoptotic cell death can be triggered by
various stimuli, including engagement and activation
of death receptors belonging to the TNF receptor
(TNFR) superfamily (TNFR-1, Fas/Apo1/CD95, DR3/Apo3,
TRAIL-R1, TRAIL-R2, and DR6) (for review see Ashkenazi and
Dixit, 1999). Death receptor mediated apoptosis has been shown to
be crucial to the proper homeostasis and function of the immune
system (Nagata, 1997; Ashkenazi and Dixit, 1999).
Fas ligand (FasL, CD95L), the prototype death ligand, has been
shown to be one of the two major effector molecules of cytolytic T
lymphocyte (CTL)-mediated cytotoxicity (KaÈgi et al, 1994a, b;
Lowin et al, 1994a, b). CTL-mediated cytolysis involves transient
expression of FasL on activated lymphocytes, and subsequent
cytolysis of Fas-bearing target cells following Fas-FasL cross-
linking. A functional Fas signaling pathway in tumor cells is
therefore a prerequisite for effective Fas-mediated tumor cell
destruction by the immune system. TRAIL, a more recently
identi®ed ligand for the death receptors TRAIL-R1 and R2, has
been shown to quite selectively induce tumor cell death, and is
expressed upon activation of T cells, natural killer cells, monocytes,
and blood dendritic cells (Ashkenazi and Dixit, 1998; Thomas and
Hersey, 1998; Zamai et al, 1998; Fanger et al, 1999; Grif®th et al,
1999; Kayagaki et al, 1999). TRAIL has recently been found to
mediate CD4 CTL-mediated killing of Jurkat T cells, autologous
and allogeneic melanoma cells in vitro, including FasL-resistant
melanoma cells (Kayagaki et al, 1999; Thomas and Hersey, 1998).
Taken together evidence now exists suggesting that death receptor
signaling mediated by FasL and TRAIL may be implicated in the
cellular immune response to melanoma. Consequently, inhibition
of these death receptor pathways may favor immune escape.
Recently, a new family of viral inhibitors of death receptor-
mediated cell death, named viral FLIP (FADD-like IL1b-converting
enzyme (FLICE)/caspase-8 inhibitory proteins) (vFLIP) has been
identi®ed, and shown to act as dominant negative inhibitors of
FADD, a crucial mediator of death receptor signaling (Thome et al,
1997). A human cellular homolog of FLIP (also called CASPER,
iFLICE, FLAME-1, CASH, CLARP, MRIT, and Usurpin) was
subsequently identi®ed, and shown to exist in two protein forms: a
long form (FLIPL) containing two death effector domains (DED)
and an inactive caspase domain, and a short form (FLIPS), containing
only two DED (Irmler et al, 1997). Overexpression of FLIP has been
shown to potently inhibit death receptor-mediated apoptosis by
binding to FADD and caspase-8 and thus speci®cally inhibit
apoptosis mediated by all currently known death receptors
(Goltsev et al, 1997; Hu et al, 1997; Irmler et al, 1997; Rasper et al,
1998). FLIP is detectable in melanoma cell lines in vitro (Irmler et al,
1997), and has been shown in animal tumor models to favor escape
from T cell immunity despite a functional perforin-granzyme
cytolytic pathway (Djerbi et al, 1999; Medema et al, 1999). Because
little is known about FLIP expression with respect to human
tumorigenesis in vivo, we have immunohistochemically analyzed
FLIP expression in biopsies of cutaneous melanocytic lesions with
respect to tumor progression and assessed its effect on TRAIL
sensitivity in FLIP-transfected melanoma cell lines.
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MATERIALS AND METHODS
Tissue samples Sixty-one paraf®n-embedded cutaneous melanocytic
lesions were used for immunohistochemical analysis. The histologic
diagnoses were as follows: 23 common nevi, nine atypical nevi, eight
super®cial spreading melanomas (mean Breslow index 0.66 mm, range
0.25±1.25), 10 nodular melanomas (mean Breslow index 5.17 mm, range
1.66±10.5), 11 cutaneous metastatic melanomas.
Antibodies and recombinant proteins Two polyclonal antibodies
(AL129 and AL148) directed against distinct recombinant fragments of
human FLIP were generated in rabbits (Eurogentec, Seraing, Belgium)
and controlled for speci®city by immunoblotting of protein extracts from
human FLIP- or mock-transfected Jurkat cells.
Recombinant soluble Flag-tagged TRAIL and FasL (Alexis, San
Diego, CA) were used at 100 ng per ml and mixed with enhancer
(Alexis) at 1 mg per ml to increase the activity of TRAIL and FasL
through aggregation.
Immunohistochemistry Paraf®n-embedded (6 mm) tissue sections
mounted on silane-treated slides were deparaf®nized in xylene,
rehydrated, and processed for antigen retrieval by microwave heating
(710 W) for 10 min in citrate buffer (10 mM, pH 6). Endogenous
peroxidase activity was quenched with 0.03% H2O2 and nonspeci®c
binding prevented by preincubation in PBS-1% BSA. For FLIP analysis,
the polyclonal anti-FLIP antibodies AL129 and AL148 were used at a
concentration of 25 mg per ml in PBS-1% BSA-0.05% Tween. Isotype-
matched rabbit IgG was used at the same concentration as a negative
control. Antibody-coated slides were incubated in a humid chamber for
2 h, washed twice in PBS, incubated for 40 min with biotin-conjugated
antirabbit-IgG diluted (1:250 in PBS-1% BSA-0.05% Tween), followed
by 30 min streptavidin-peroxidase (StreptABComplex/HRP, Dako,
Glostrup, DK). After another wash, 3-amino-9-ethylcarbazole (AEC) and
H2O2 were added for 10 min, and then slides were washed and
counterstained with hematoxylin.
Semiquantitative analysis of intensity of FLIP immunostaining intensity
was performed by rating staining intensity as follows: 0, no staining; 1,
weak staining; 2, moderate staining; 3, strong staining. In all experiments
similar results were obtained using both antihuman FLIP antibodies
(AL129 and AL148).
Morphometric analysis of the percentage of melanocytic cells express-
ing FLIP was performed by counting a minimum of 200 melanocytes
per immunostained section.
Immunoblotting Whole cell lysates (50 mg) were resolved in 10%
SDS-PAGE, transferred to nitrocellulose, and blotted with polyclonal
antihuman FLIP antibody (AL129 or AL148, 1 mg per ml) for 1 h, then
incubated for 45 min with HRP-conjugated antirabbit IgG (Jackson
Immunoresearch Laboratories, West Grove, PA) at a 1:2000 dilution.
Signals were detected using the ECL system (Amersham, Arlington
Heights, IL).
Cell culture and FLIP transfection The human melanoma cell line
WK, derived from a primary cutaneous melanoma of super®cial speading
type was cultured on plastic in minimal essential media (MEM) with
Earle's balanced salt solution supplemented with 10% fetal calf serum and
maintained at 37°C in a humidi®ed atmosphere of 5% CO2, 95% air
(Byers et al, 1991). Stable geneticin-resistant transfectants of WK cells
were generated by electroporation of 5 3 106 cells in 800 ml PBS,
mixed with pCR-3 (Invitrogen) plasmid with or without the human
FLIP insert, at 250 V and 960 mF. Starting 48 h after transfection,
geneticin was added at 400 mg per ml until growth of resistant clones.
Resistant clones were isolated, ampli®ed, and analyzed for FLIP gene
expression using reverse transcriptase-polymerase chain reaction (RT-
PCR).
Extraction of RNA and RT-PCR Total RNA was prepared from
cells using TRIzol Reagent (Gibco BRL, Life Technology, Basel,
Switzerland). Brie¯y, cells were lyzed by adding 1 ml of TRIzol
Reagent, RNA was precipitated from the aqueous phase and
resuspended in water.
Total mRNA (500 ng) was reverse transcribed and ampli®ed using a
one-step RT-PCR kit (Acees RT-PCR System, Promega, Madison,
WI). The nucleotide sequences of the sense and antisense primers for
FLIP were 5¢-ATTGGTGAGGATTTGGATAA-3¢ and 5¢-TGGGCG-
TTTTCTTTCTTGTC-3¢, respectively. For actin, the sense and anti-
sense primers were 5¢-TGATGGACTCCGGTGACGG-3¢ and 5¢-TGT-
CACGCACGATTTCCCGC-3¢, respectively. Ampli®cation was carried
out for 25 cycles using a step-cycle that consisted of denaturation [94°C;
1 min (for FLIP) or 94°C; 30 s (for actin)], annealing [55°C; 30 s (for
FLIP) or 62°C; 1 min (for actin)] and extension [72°C; 1 min (for FLIP)
or 68°C; 2 min (for actin)]. The ®nal extension was allowed to proceed
for 7 min. After PCR, 10% (i.e., 5 ml) of each reaction mixture were
subjected to electrophoresis on a 1% agarose gel containing 0.5 mg per
ml ethidium bromide in 1 3 Tris-acetate electrophoresis buffer. The gel
was photographed under ultraviolet light.
Measurement of TRAIL- and FasL-mediated cell death 104 cells
resuspended in 50 ml were plated in 96 well microtiter plates and
allowed to adhere. After adhesion, recombinant soluble TRAIL (or FasL)
plus enhancer (Alexis) diluted in 50 ml culture medium were added in
order to obtain a ®nal TRAIL (or FasL) concentration of 100 ng per ml
and an enhancer concentration of 1 mg per ml. Control wells received
50 ml of culture medium alone. Cell viability was assessed after 16 h
using the WST-1 cell proliferation kit according to manufacturer's
instructions (Roche Diagnostics, Rotkreuz, Switzerland). Brie¯y, 10 ml
of WST-1 reagent was added to each well and incubated at 37°C for
45 min. Thereafter absorbance was measured at 450 nm. Cell survival
after TRAIL (or FasL) addition was calculated with respect to control
cells having received culture medium alone.
RESULTS
Speci®city of anti-FLIP antibodies The speci®city of the
polyclonal Ab was tested by immunoblotting of protein extracts
from Jurkat cells transfected with human FLIP. Both anti-FLIP Ab
AL129 (Fig 1A) and AL148 (not shown) selectively detected a
band of the expected size (55 kDa) in the FLIP transfected cell line
that was shown to have acquired resistance to FasL and TRAIL
(Fig 1B). We further tested the speci®city of these antibodies using
cells cultured in vitro. Immunohistochemical data obtained on
cytospins of wild-type and FLIP-transfected Jurkat cells with the
same antibodies used for the immunohistochemical study perfectly
correlated with FLIP expression as quanti®ed by RNase protection
and western blot on the same cells (data not shown).
FLIP expression in benign melanocytic skin lesions FLIP
expression was analyzed using both anti-FLIP polyclonal Ab in 23
common nevi and nine atypical nevi. As shown in Figs 2 and 3,
FLIP expression was undetectable in 22 of 23 common nevi and all
Figure 1. The AL129 antibody speci®cally recognizes FLIP
protein. (A) Immunoblot analysis of lysates from FLIP- (left lane) and
mock-transfected Jurkat cells using the rabbit antihuman FLIP antibody
AL129. (B) Sensitivity of Jurkat and Jurkat-FLIP cells to recombinant
FasL and TRAIL.
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nine atypical nevi. Taken together, only one of 32 (3%) benign
melanocytic lesions expressed detectable, although weak, levels of
FLIP.
FLIP expression in melanoma Immunohistochemical
analysis of FLIP expression in melanomas revealed strong
expression in six of eight (75%) super®cial spreading melanomas
(mean Breslow index 0.66 mm, range 0.25±1.25), nine of 10 (90%)
nodular melanomas (mean Breslow index 5.17 mm, range 1.66±
10.5), and nine of 11 (82%) cutaneous metastatic melanomas
(Figs 2, 3). Melanocytic expression of FLIP within the malignant
melanocytic lesions was in all cases cytoplasmic as expected (Fig 2).
In SSM and nodular melanomas, FLIP expression was less
homogeneous throughout the tumor than in metastatic
melanoma, where virtually all tumor cells were FLIP positive
(Figs 2, 4). By morphometric analysis, FLIP staining was observed
in 50% of SSM cells, 100% of nodular melanoma cells, and 100% of
metastatic melanoma cells (Fig 4). It therefore clearly appears that
the percentage of FLIP positive tumor cells within a melanocytic
lesion increases with melanoma progression.
Melanoma cells overexpressing FLIP are more resistant to
FasL and TRAIL To determine if the high levels of FLIP
expression observed in malignant melanocytic lesions could
account for resistance to death-receptor signaling and apoptosis,
we transfected one of the rare human melanoma cell lines that we
were able to identify as being sensitive to TRAIL and FasL-induced
apoptosis, with a human FLIP expression vector. Four clones were
selected by RT-PCR (Fig 5A) and tested for sensitivity to
recombinant TRAIL and FasL (Fig 5B, C). All FLIP-transfected
clones were signi®cantly more resistant to both TRAIL- and FasL-
mediated apoptosis as compared with the mock-transfected WK
melanoma cell line.
DISCUSSION
FLIP, a potent intracellular inhibitor of apoptotic cell death
mediated by death receptor signaling, was originally discovered as a
family of viral inhibitors of death receptor-mediated cell death
found in several herpesviruses (including oncogenic HHV8/
Kaposi's sarcoma associated herpesvirus and molluscipox virus).
Cellular homologs of viral FLIP were subsequently identi®ed, and
shown to be expressed in certain tumor cell lines; however,
involvement of FLIP in the resistance of tumor cell lines to Fas-
mediated death is controversial because a correlation between FLIP
expression and resistance to death receptor-mediated cell death was
observed in some studies (Grif®th et al, 1998), but not others
(Ugurel et al, 1999; Zhang et al, 1999). Therefore the in vivo
relevance of the data obtained from the study of tumor cell lines
remains unclear.
Figure 2. Selective expression of FLIP in
melanomas. (A±C) Immunohistochemical
staining with AL129 anti-FLIP antibody of an
atypical nevus (A), a super®cial spreading
melanoma (B), and a nodular melanoma (C),
showing increased FLIP expression in malignant
melanocytic skin lesions (B and C) as compared
with benign ones (A). (D) Immunohistochemical
staining of a nodular melanoma with an isotype-
matched antibody. Scale bar: 100 mm.
Figure 3. Semiquantitative analysis of FLIP expression in 61
benign and malignant human melanocytic skin lesions.
Semiquantitative evaluation of the FLIP immunohistochemical staining
intensity in the melanocytic component of common benign melanocytic
nevi (CBMN), atypical nevi (AN), super®cial spreading melanomas
(SSM), nodular melanomas (NM), and cutaneous melanoma metastases
(CMM). 0, no staining; +, weak staining; ++, moderate staining; +++,
strong staining. Similar results were obtained using another rabbit
antihuman FLIP antibody (AL148).
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Here we provide data concerning the in situ expression of FLIP
in human melanomas, and its potential relevance to tumor
development. We show by immunohistochemical analysis of 61
benign and malignant human melanocytic skin lesions that FLIP is
selectively overexpressed in malignant melanocytic lesions of the
skin, namely super®cial spreading melanomas, nodular melanomas,
and cutaneous metastases of melanoma. FLIP expression was
detected in only one of 32 benign melanocytic lesions, and at low
levels. In contrast, expression was observed in 75% (six of eight) of
super®cial spreading melanomas, 90% (nine of 10) nodular
melanomas, and 82% (nine of 11) of cutaneous melanoma
metastases. Furthermore, within tumors, the percentage of cells
expressing FLIP increased with progression, 50% of cells being
FLIP-positive in SSM versus 100% in nodular melanoma and
cutaneous metastatic melanoma. It clearly appears therefore that
FLIP expression is more frequent in malignant melanocytic lesions,
suggesting that it may, in certain cases, be implicated in the
pathogenesis of melanoma, possibly by offering distinct advantages
to the tumor cells. Here we show by transfection that over-
expression of FLIP in melanoma cells renders them signi®cantly
more resistant to the pro-apoptotic effect of recombinant FasL and
TRAIL.
Recent evidence has suggested that defective Fas-signaling due
to loss of Fas expression or inhibition by FLIP, may be implicated
in tumorigenesis. Indeed, loss of Fas expression or function has
been demonstrated in several malignant tumors (Moller et al, 1994;
Robertson et al, 1995; Lebel et al, 1996; Strand et al, 1996; Butler
et al, 1998). Furthermore, loss of Fas expression has been shown to
favor survival, proliferation, and eventually tumor formation in
mouse models by preventing Fas-FasL mediated fratricide that
occurs in three-dimensional settings if tumor cells express both Fas
and FasL (Peli et al, 1999; Schroter et al, 2000). Likewise, in murine
tumor models, inhibition of Fas signaling by overexpression of
FLIP confers an advantage to tumors within an immunocompetent
setting (Djerbi et al, 1999; Medema et al, 1999). Escaping death-
receptor mediated cell death may therefore, at least in certain tumor
types, enable tumors to grow in three dimensions and/or evade
elimination by the immune system.
The resistance to FasL or TRAIL in vitro is a complex and
multifaceted phenomenon, that at least in vitro does not simply
correlate with a single factor, as for instance the basal level of FLIP.
Nothwithstanding, our data showing strong FLIP expression in vivo,
along with a correlation with loss of sensitivity to FasL and TRAIL
after FLIP-transfection in vitro, may be of relevance in vivo given the
mouse experiments referred to above and relatively new data
showing that TRAIL mediates CD4 CTL target cell killing,
including that of certain FasL resistant melanoma cells (Thomas and
Hersey, 1998; Kayagaki et al, 1999). Inhibition of Fas and TRAIL-
Receptor signaling by FLIP may therefore signi®cantly inhibit the
immune effector response to melanoma. Furthermore, taken
together with the recent reports showing that the protein kinase
C inhibitor bisindolylmaleimide sensitizes cells to Fas via down-
regulation of FLIP expression (Willems et al, 2000; Zhou et al,
1999), pharmacologic modulation of FLIP expression may be of
interest as a potential therapeutic approach for melanoma.
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